Information about Troglitazone
Troglitazone was the first thiazolidinedione approved for use in the United States and was licensed for use in type 2 diabetes in 1997, but withdrawn 3 years later because of the frequency of liver injury including acute liver failure associated with its use.
Mechanism of action of Troglitazone
Troglitazone (troe gli' ta zone) is an insulin sensitizing agent thought to act by engagement of PPAR-? receptors which induce multiple genes involved in glucose and fatty acid metabolism. In clinical trials, troglitazone was found to lower blood glucose and HbA1c levels and had additive effects with the sulfonylureas and metformin.
FDA approval information for Troglitazone
Troglitazone was approved for use in the United States in 1997 to be used alone or in combination with other antidiabetic medications. However, reports of severe liver injury and death from acute liver failure began to arise soon after its general availability, and it was withdrawn from use in 2000. Troglitazone was sold under the brand name Rezulin and was available in 400 mg tablets.
Dosage and administration for Troglitazone
The recommended dosage was 400 to 800 mg once daily. Troglitazone was used as monotherapy as well as in combination with metformin, sulfonylureas or insulin.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors
Cost and Coupons - Troglitazone
- GoodRx compare cost & coupons for Troglitazone
- Find the lowest cost of Troglitazone
- Search for Coupons for Troglitazone
Reviews for Troglitazone